J 2022

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

BLENNOW, Ola, Jon SALMANTON-GARCIA, Piotr NOWAK, Federico ITRI, Van Doesum JAAP et. al.

Basic information

Original name

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Authors

BLENNOW, Ola, Jon SALMANTON-GARCIA (guarantor), Piotr NOWAK, Federico ITRI, Van Doesum JAAP, Alberto LOPEZ-GARCIA, Francesca FARINA, Ozren JAKSIC, Laszlo Imre PINCZES, Yavuz M BILGIN, Iker FALCES-ROMERO, Moraima JIMENEZ, Irati ORMAZABAL-VELEZ, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Remy DULERY, Zlate STOJANOSKI, Tobias LAHMER, Noemi FERNANDEZ, Jose-angel HERNANDEZ-RIVAS, Verena PETZER, De Jonge NICK, Andreas GLENTHOJ, De Ramon CRISTINA, Monika M BIERNAT, Nicola FRACCHIOLLA, Avinash AUJAYEB, Van Praet JENS, Martin SCHONLEIN, Gustavo-Adolfo MENDEZ, Chiara CATTANEO, Anna GUIDETTI, Mariarita SCIUME, Emanuele AMMATUNA, Raul CORDOBA, Nicole GARCIA-POUTON, Stefanie GRAEFE, Alba CABIRTA, Dominik WOLF, Anna NORDLANDER, Ramon GARCIA-SANZ, Mario DELIA, Berg Venemyr CAROLINE, Clara BRONES, Di Blasi ROBERTA, De Kort ELIZABETH, Stef MEERS, Sylvain LAMURE, Laura SERRANO, Maria MERELLI, Nicola COPPOLA, Rui BERGANTIM, Caroline BESSON, Milena KOHN, Jessica PETITI, Carolina GARCIA-VIDAL, Michelina DARGENIO, Francois DANION, Marina MACHADO, Rebeca BAILEN-ALMOROX, Martin HOENIGL, Giulia DRAGONETTI, Louis Yi Ann CHAI, Chi Shan KHO, Matteo BONANNI, Raphael LIEVIN, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO

Edition

American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 12.800

RIV identification code

RIV/00216224:14110/22:00127656

Organization unit

Faculty of Medicine

UT WoS

000816988100001

Keywords in English

omicron SARS-CoV-2 variant; hematological malignancies

Tags

Tags

International impact, Reviewed
Změněno: 4/1/2023 12:34, Mgr. Tereza Miškechová

Abstract

V originále

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.